165 related articles for article (PubMed ID: 17020686)
1. [Review of the scientific evidence of the efficiency of erythropoietin use].
García-Altés A; Puig-Junoy J
Med Clin (Barc); 2006 Sep; 127(11):415-20. PubMed ID: 17020686
[No Abstract] [Full Text] [Related]
2. [Use of recombinant erythropoietin in the treatment of anemia of chronic renal insufficiency].
Drüeke T; Zins B; Bererhi L; Casadevall N; Varet B
Presse Med; 1989 Jun; 18(25):1235-7. PubMed ID: 2525772
[No Abstract] [Full Text] [Related]
3. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure].
Schaefer RM; Heidland A
Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190
[No Abstract] [Full Text] [Related]
4. [The recovery of erythropoiesis after the short-term Recormon treatment of renal anemia].
Nikolaev AIu; Klepikov PV; Lashutin SV
Ter Arkh; 1992; 64(6):90-1. PubMed ID: 1440349
[No Abstract] [Full Text] [Related]
5. The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels.
Kooistra MP; Struyvenberg A; van Es A
Nephron; 1991; 57(1):127-8. PubMed ID: 2046808
[No Abstract] [Full Text] [Related]
6. Neocytolysis: from outer space to the dialysis unit.
Means RT
Am J Kidney Dis; 1999 Jan; 33(1):140-1. PubMed ID: 9915281
[No Abstract] [Full Text] [Related]
7. Hemoglobin F levels in end-stage renal disease patients after correction of anemia with erythropoietin.
Sikole A; Efremov DG; Dimovski A; Efremov GD; Polenakovic M
Nephron; 1993; 65(3):482-4. PubMed ID: 7507224
[No Abstract] [Full Text] [Related]
8. Hemoglobin normalization studies.
Reddan D; Lappin DW; Tierney M; Szczech LA
Perit Dial Int; 2007; 27(4):395-9. PubMed ID: 17602145
[No Abstract] [Full Text] [Related]
9. Erythropoietin.
Beresford CH
N Z Med J; 1989 Apr; 102(866):185-6. PubMed ID: 2652007
[No Abstract] [Full Text] [Related]
10. Erythropoiesis-stimulating agents in kidney and cardiac disease.
Fluck R
Br J Hosp Med (Lond); 2006 Oct; 67(10):533-7. PubMed ID: 17069130
[No Abstract] [Full Text] [Related]
11. Effects of recombinant human erythropoietin treatment in end-stage renal failure patients. Results of a multicenter phase II/III study.
Pollok M; Bommer J; Gurland HJ; Koch KM; Schoeppe W; Scigalla P; Baldamus CA
Contrib Nephrol; 1989; 76():201-11; discussion 212-8. PubMed ID: 2684523
[No Abstract] [Full Text] [Related]
12. Pathogenesis of uremic anemia and new therapeutic prospectives.
Lamperi S; Carozzi S; Icardi A; Nasini MG; Traverso GB
Contrib Nephrol; 1989; 69():190-4; discussion 195-6. PubMed ID: 2661141
[No Abstract] [Full Text] [Related]
13. Management of the anaemia of chronic renal failure with recombinant erythropoietin.
Adamson JW; Eschbach JW
Q J Med; 1989 Dec; 73(272):1093-101. PubMed ID: 2694210
[No Abstract] [Full Text] [Related]
14. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
Sobota JT
Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
[No Abstract] [Full Text] [Related]
15. [Variability of the hemoglobin level: each patient is unique].
Zaoui P; Deray G; Ortiz JP; Rostaing L
Nephrol Ther; 2011 Feb; 7(1 Suppl 2):H1-4. PubMed ID: 21371677
[No Abstract] [Full Text] [Related]
16. Response to recombinant human erythropoietin (rHu-Epo) in a patient with chronic renal failure and myelomonocytic leukaemia.
Salvati F; Liani M; Bonomini M
Nephrol Dial Transplant; 2001 Jan; 16(1):191-2. PubMed ID: 11209030
[No Abstract] [Full Text] [Related]
17. Dose-finding, double-blind, clinical trial of recombinant human erythropoietin (Chugai) in Japanese patients with end-stage renal disease. Research Group for Clinical Assessment of rhEPO.
Suzuki M; Hirasawa Y; Hirashima K; Arakawa M; Odaka M; Ogura Y; Yoshikawa Y; Sanaka T; Shinoda A; Morii H
Contrib Nephrol; 1989; 76():179-92; discussion 212-8. PubMed ID: 2684520
[No Abstract] [Full Text] [Related]
18. Erythropoietin for anemia.
Med Lett Drugs Ther; 1989 Sep; 31(801):85-6. PubMed ID: 2671624
[No Abstract] [Full Text] [Related]
19. Resistance to recombinant human erythropoietin in a hemodialysis patient with lupus reactivation.
Romero R; Novoa D; Perez-Freiria A; Arcocha V; Alonso R; Arza D; Lens XM; Sanchez-Guisande D
Nephron; 1995; 69(3):343-4. PubMed ID: 7753275
[No Abstract] [Full Text] [Related]
20. Recombinant human Epo treatment: beneficial in chronic kidney disease, chronic heart failure, or both? Editorial to: "Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance by Pappas et al.".
Belonje AM; de Boer RA; Voors AA
Cardiovasc Drugs Ther; 2008 Feb; 22(1):1-2. PubMed ID: 18219567
[No Abstract] [Full Text] [Related]
[Next] [New Search]
